Table 1.
Baseline characteristics of patients according to Symptomatic hemorrhagic transformation (sHT).
| Parameter (Unit) | Total (n = 51) |
no-sHT (n = 41) |
sHT (n = 10) | p Value | |
|---|---|---|---|---|---|
| Age (years) | 67 (55–78) | 63 (54–76) | 74 (67–79) | 0.138 | |
| SEX-male N/total (ratio) | 22/51 (0.43) | 17/41 (0.41) | 5/10 (0.50) | 0.631 | |
| BMI [kg/m2] | 27 (24–32) | 26 (24–32) | 28 (25–31) | 0.887 | |
| Medical history, N/total (ratio) | CAD | 13/51 (0.25) | 8/41 (0.20) | 5/10 (0.50) | 0.055 |
| Previous AIS | 6/51 (0.12) | 6/41 (0.15) | 0/10 | 0.198 | |
| Hypertension | 38/51 (0.75) | 29/41 (0.71) | 9/10 (0.90) | 0.215 | |
| Diabetes mellitus | 16/51 (0.31) | 12/41 (0.29) | 4/10 (0.40) | 0.509 | |
| Dyslipidemia | 28/51 (0.55) | 24/41 (0.59) | 4/10 (0.40) | 0.291 | |
| AF | 15/51 (0.29) | 10/41 (0.24) | 5/10 (0.50) | 0.118 | |
| Anticoagulant therapy N/total (ratio) | VKA | 5/51 (0.10) | 3/41 (0.07) | 2/10 (0.20) | 0.231 |
| Antiplatelets | 14/51 (0.27) | 12/41 (0.29) | 2/10 (0.20) | 0.567 | |
| Current smokers, N/total (ratio) | 13/51 (0.25) | 11/41 (0.27) | 2/10 (0.20) | 0.664 | |
| SBP (mmHg) | 130 (130–150) | 130 (130–150) | 158 (140–180) | 0.009 | |
| DBP (mmHg) | 80 (80–90) | 80 (80–80) | 90 (80- 100) | 0.027 | |
| LVEF (%) | 60 (50–65) | 60 (50–65) | 60 (55–60) | 0.374 | |
| AST (U/L) | 19 (16–25) | 19 (16–24) | 20 (17–29) | 0.313 | |
| ALT (U/L) | 17 (13–22) | 17 (13–25) | 16 (12–19) | 0.265 | |
| sCr (mg/dL) | 0.85 (0.71–1.08) | 0.81 (0.69–1.03) | 1.07 (0.80–1.15) | 0.024 | |
| LDL (mg/dL) | 89 (73–132) | 94 (73–138) | 78 (74–119) | 0.553 | |
| Glucose (mg/dL) | 125 (107–151) | 122 (109–150) | 134 (107–151) | 0.537 | |
| CBC | WBCs (103/μL) | 10.88 (8.70–13.30) | 10.75 (8.67–13.05) | 12.06 (10.04–17.94) | 0.132 |
| NEUTs (103/μL) | 8.65 (6.51–12.49) | 8.00 (5.95–9.69) | 13.18 (8.52–15.58) | 0.034 | |
| LYMPHs (103/μL) | 1.64 (1.04–2.13) | 1.76 (1.13–2.32) | 1.13 (0.75–1.63) | 0.012 | |
| MONOs (103/μL) | 0.94 (0.71–1.15) | 0.94 (0.71–1.13) | 1.00 (0.66–1.33) | 0.469 | |
| RBCs (106/μL) | 4.31 (3.99–4.69) | 4.31 (3.99–4.61) | 4.33 (4.07–5.06) | 0.545 | |
| HGB (g/dL) | 13.3 (12.1–14.2) | 13.3 (11.9–14.2) | 13.1 (12.1–14.3) | 0.367 | |
| HCT (%) | 38.2 (36.0–42.5) | 38.2 (35.9–42.3) | 38.8 (36.1–42.7) | 0.522 | |
| PLTs (103/μL) | 233 (185–263) | 241 (206–268) | 195 (164–228) | 0.040 | |
| NLR | 5.46 (3.41–9.15) | 4.72 (3.00–8.30) | 10.39 (7.00–14.98) | 0.002 | |
| INR | 1.1 (1.0–1.2) | 1.1 (1.0–1.2) | 1.1 (1.1–1.6) | 0.155 | |
| aPTT | 26.4 (25.0–29.8) | 26.2 (25.0–29.8) | 26.9 (25.1–28.5) | 0.831 | |
Data are expressed as median (interquartile range, IQR) or frequencies and ratios. The p values were determined using the Pearson’s χ2 tests (categorical variables) or the Mann–Whitney U test (continuous variables). Abbreviations: n: number, BMI: body mass index, CAD: coronary artery disease, AIS: acute ischemic stroke, and AF: atrial fibrillation, VKA: vitamin K antagonists. SBP: systolic blood pressure, DBP: diastolic blood pressure, LVEF: left ventricular ejection fraction, AST: aspartate aminotransferase, ALT: alanine aminotransferase, sCr: serum creatinine, LDL: low-density lipoprotein, CBC: complete blood count, WBCs: white blood cells, NEUTs: neutrophils, LYMPHs: lymphocytes, MONOs: monocytes, RBCs: red blood cells, PLTs: platelets, NLR: neutrophil-to-lymphocyte ratio, INR: international normalized ratio, aPTT: activated partial thromboplastin time.